|
|
Copyright © LARVOL 2024. All rights reserved. Visit SABCS 2019: Residual cancer burden in patients with early stage triple (https://clin.larvol.com/abstract-detail/SABCS%202019/35256487)
|
Top Keywords: 2019, sabcs, cancer, in patients with, with early, in patients, early stage, patients with, residual, burden, triple, stage, patients, early, trials, influencers, conferences, reserved, terms of service, of service, triple negative breast cancer, negative breast cancer, triple negative breast, all rights reserved, figures for, triple negative, an ongoing, progress on, rights reserved, all rights, clinical trial, breast cancer, anthracycline, neoadjuvant, chemotherapy, artemis, Theres a total of 53 keywords.
Inbound and Outbound LinksThere is currently no known inbound links. There is currently no known outbound links. |
Statistics
We first found this page on 2023-03-25 00:00:07 +0000. It was last re-indexed on 2024-09-26 13:00:54 +0000 and with a fetch interval of 90 days it will be fetched again in 40 days on 2024-12-25 or soon thereafter.
Last fetch returned code 200, OK, the current page state is ACTIVE.
Traffic Data for clin.larvol.com
Traffic data is only available for sites with a CashRank of $15 or better, an Alexa rank better than 100,000 or PageRank of 2 or more.If you are the owner of /clin.larvol.com and you want to remove this page from the search results, just use robots.txt
Similar Sites
BL-M07D1 / Biokin Pharma
News for BL-M07D1 / Biokin Pharma
https://delta.larvol.com/Products/?ProductId=d49ca0a7-de14-47df-8b88-ced1d09ea68f
- Details - Similar
anastrozole / Generic mfg.
News for anastrozole / Generic mfg.
https://delta.larvol.com/products/?ProductId=4450b1a4-00d1-43ef-be59-c939ed86d5b3&Index=0
- Details - Similar
RINVOQ® (upadacitinib) for Atopic Dermatitis
Learn about RINVOQ®, a JAK inhibitor for the treatment of adults and pediatric patients with refractory, moderate to severe atopic dermatitis. See full Prescribing and Safety Information, and BOXED WARNING.
https://www.rinvoqhcp.com/atopic-dermatitis
- Details - Similar
RINVOQ® (upadacitinib) | Official Healthcare Professional Site
RINVOQ® (upadacitinib) is approved for treatment of certain patients with RA, PsA, AD, UC, AS, nr-axSpA, CD and pJIA. See full Prescribing, Use Safety Info, and BOXED WARNING
https://www.rinvoqhcp.com/
- Details - Similar
More sites similar to SABCS 2019: Residual cancer burden in patients with early stage triple...
Find Another Website
Sponsored Results
Your Ad Here & Hundreds of Other ISEDN Engines & Directories- $3/Month or Less
Your Ad Here & Hundreds of Other ISEDN Engines & Directories- $3/Month or Less